Billionaire Stanley Druckenmiller Dropped Nvidia and Palantir Stock and Is Piling into 2 Stocks Set to Win in One of the Decade's Hottest Growth Markets.The Motley Fool • 11/05/25
Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025PRNewsWire • 10/29/25
Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales NilZacks Investment Research • 10/23/25
Viking Therapeutics Q3 Earnings: What We Learned (And Why We Should Keep Faith)Seeking Alpha • 10/23/25
Viking Bolts Higher On 'Lightning' Speed Enrollment In Obesity StudiesInvestors Business Daily • 10/23/25
Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdatePRNewsWire • 10/22/25
Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with ObesityPRNewsWire • 10/21/25
Pre-Q3 Earnings: Is Viking Therapeutics Stock a Portfolio Must-Have?Zacks Investment Research • 10/17/25
Eli Lilly vs. Viking Therapeutics Stock: Which Is the Best Growth Opportunity, According to Wall Street?The Motley Fool • 10/17/25
Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025PRNewsWire • 10/15/25